(Q35069652)

6 August 2017

0 references

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer (English)

1 reference

6 August 2017

phase I clinical trial

0 references

1 reference

13

Kyoung-Mee Kim

1 reference

6 August 2017

Taekyu Lim

1

1 reference

6 August 2017

Jeeyun Lee

2

1 reference

6 August 2017

Duk Joo Lee

3

1 reference

6 August 2017

Ha Yeon Lee

4

1 reference

6 August 2017

Boram Han

5

1 reference

6 August 2017

Kyung Kee Baek

6

1 reference

6 August 2017

Hee Kyung Ahn

7

1 reference

6 August 2017

Su Jin Lee

8

1 reference

6 August 2017

Se Hoon Park

9

1 reference

6 August 2017

Joon Oh Park

10

1 reference

6 August 2017

Young Suk Park

11

1 reference

6 August 2017

Ho Yeong Lim

12

1 reference

6 August 2017

Won Ki Kang

14

1 reference

6 August 2017

28 April 2011

1 reference

Cancer Chemotherapy and Pharmacology

6 August 2017

1 reference

6 August 2017

68

1 reference

6 August 2017

1

1 reference

6 August 2017

255-262

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-011-1653-5

6 August 2017

0 references

cites work

Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

The role of mTOR in the management of solid tumors: an overview

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

Capecitabine as adjuvant treatment for stage III colon cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

The role of chemotherapy in the current treatment of gastric cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3123695

Annual Report of the Korea Central Cancer Registry Program 2000: Based on Registered Data from 131 Hospitals

8 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1653-5

Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1653-5

Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1653-5

Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1653-5

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1653-5

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1653-5

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21526353

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21526353

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21526353

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00280-011-1653-5

1 reference

6 August 2017

1 reference

6 August 2017

1 reference